Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
CLRB
vs
S&P 500
CLRB
S&P 500
Over the past 12 months, CLRB has underperformed S&P 500, delivering a return of -70% compared to S&P 500's +19% growth.
Stocks Performance
CLRB vs S&P 500
Performance Gap
CLRB vs S&P 500
Performance By Year
CLRB vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Cellectar Biosciences Inc
Glance View
Cellectar Biosciences is a clinical-stage biopharma company focused on cancer drugs. It builds therapies around a phospholipid drug conjugate platform, which is designed to carry cancer-killing drugs more directly to tumor cells while limiting exposure to healthy tissue. Its work is centered on developing treatment candidates for hard-to-treat blood cancers and solid tumors. The company does not sell a broad range of commercial medicines. Instead, it spends most of its effort on research, clinical development, and regulatory work for its drug candidates. If its programs succeed, it can make money through drug sales, licensing deals, or partnerships with larger pharmaceutical companies. Today, its main “customers” are really the future patients, doctors, and drug partners that would use or help commercialize its therapies. What makes Cellectar different is its role as a technology-driven drug developer rather than a traditional drug seller. Its value comes from owning a drug-delivery platform that it can apply to different cancer targets, which gives it several shots at building products from the same core science. That makes it a high-risk, research-focused business model where success depends on proving that its platform can turn promising lab science into approved cancer treatments.